You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Livia Bernardi + 1575 word(s) 1575 2021-11-25 09:04:15 |
2 format correct Catherine Yang Meta information modification 1575 2022-01-13 09:02:32 | |
3 format correct Catherine Yang Meta information modification 1575 2022-01-13 09:49:31 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Bernardi, L. Prion Protein Gene. Encyclopedia. Available online: https://encyclopedia.pub/entry/18180 (accessed on 22 December 2025).
Bernardi L. Prion Protein Gene. Encyclopedia. Available at: https://encyclopedia.pub/entry/18180. Accessed December 22, 2025.
Bernardi, Livia. "Prion Protein Gene" Encyclopedia, https://encyclopedia.pub/entry/18180 (accessed December 22, 2025).
Bernardi, L. (2022, January 13). Prion Protein Gene. In Encyclopedia. https://encyclopedia.pub/entry/18180
Bernardi, Livia. "Prion Protein Gene." Encyclopedia. Web. 13 January, 2022.
Prion Protein Gene
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms20143606

Inherited mutations in the Prion protein (PrP), encoded by the PRNP gene, have been associated with autosomal dominant neurodegenerative disorders, such as Creutzfeldt–Jacob disease (CJD), Gerstmann–Sträussler–Scheinker syndrome (GSS), and Fatal Familial Insomnia (FFI). Notably, PRNP mutations have also been described in clinical pictures resembling other neurodegenerative diseases, such as frontotemporal dementia.

Prion protein mutation (PrP mutation) PrP N-terminal domain

1. Introduction

Prion diseases, also known as transmissible spongiform encephalopathies, are progressive, fatal, neurodegenerative disorders based on the misfolding of the prion protein [1]. They can affect both humans and a wide variety of animals, including sheep, goats, bovine, mule deer, and elk [1]. Creutzfeldt–Jakob disease (CJD), fatal familial insomnia (FFI), and Gerstmann–Sträussler–Scheinker syndrome (GSS) constitute the more common and diverse human phenotypes of prion diseases [1]. These phenotypes exhibit different characteristics based on the onset/duration of the disease, the clinical manifestations, neuropathological changes, transmissibility, and molecular features of scrapie-like prion protein (PrPSc) [2][3]. According to their etiology, human prion diseases can be divided into three groups: (1) sporadic CJD, that constitutes 85–90% of CJD cases; (2) diseases acquired by infection by external prions, such as in the case of Kuru, iatrogenic CJD, and variant CJD (2–5% of CJD cases); and (3) diseases caused by a genetic mutation in the prion (PRNP) gene, such as in the case of familial CJD, genetic CJD, GSS, and FFI (approximately, 10–15% of all prion diseases), with an autosomal dominant inheritance pattern [4]. However, the real incidence of the dominantly inherited prion diseases (IPD) is not fully known, since familial clusters have not been systematically recognized or reported [5].
A key event in the pathogenesis of infectious, sporadic, and IPD is the misfolding of the normal form of the prion protein, PrPC, into the typically protease-resistant-sheet rich isoform, defined as the scrapie prion protein (PrPSc), by a conformational rearrangement. The PrPSc constitutes the transmissible agent (“prion”), able to recruit and convert natively folded PrPC into de novo PrPSc via an autocatalytic process [6][7].

2. The Function of the Prion Protein

To date, the exact physiological role of PrP has not yet been definitively clarified. The expression of the wild type PrP is diffuse in neurons, neuroendocrine cells, and stromal cells of the lymphoreticular system. The highest levels have been observed in the central nervous system in the synaptic membrane. The determinant step in prion infection is the conversion of the conformation of PrPC into a protease-resistant β-sheet, PrPSc [2], with concomitant expression of PrPC, which is required and rate-limiting [8].
The PrP is bound to the outer membrane of the cell surface, in specific “rafts” (cholesterol- and glycosphingolipid-rich lipid sites) [9], by a glycosylphosphatidylinositol (GPI) anchor [10][11]. The N-terminal signal peptide (the first 22 amino acids of the precursor protein) is cleaved after translocation across the endoplasmic reticulum membrane [9]. The function of the physiological PrP seems to be to protect against programmed cell death [12]. The PrPC N-terminal domain binds both copper and zinc in vivo and participates in metal ion homeostasis [13]. Cu2+ and Zn2+ ions coordinate to the N-terminal PrP differently—Cu2+ interacts with the octarepeat domain, residues 60–91 with the sequence (PHGGGWGQ) [14][15], and also with residues His96 and His111 [16], whilst Zn2+ binds to the octarepeat domain, in which all four histidine residues coordinate a single Zn2+ ion [16].
PrPC is a copper-binding protein showing superoxide dismutase activity, appearing to protect against oxidative damage [17] and acting as a cell-surface receptor for signal transduction [18]. Several studies have demonstrated that the mammalian PrPC protein is extremely versatile, involved in proliferation, differentiation, cell adhesion, and synaptic plasticity [19]. Several functions of the PrPC protein depend on its interaction with extra- and intra-cellular signaling partners (ligands). Among these ligands, those found to be advantageous to the cell [19] are laminin and glycosaminoglycans (GAGs), involved in neuronal differentiation and axon growth [20], and neuronal adhesion proteins, such as N-CAM12 that contribute to neurite outgrowth [20].

3. The PRNP Gene, Mutations, and Inherited Prion Diseases

PRNP (NC_000020.11), located on chromosome 20 (4686151-4701588), is a 16 Kb long gene, containing two exons. Exon 1 has the role of a transcriptional initiation site, whereas the open reading frame (ORF) encoding the PrP protein, composed of 253 amino acids, is located in the exon 2 [21]. Different mutations have been reported as causative for diseases, but their effects have been associated with a variety of heterogeneous phenotypes [21]. Pathogenic mutations in the ORF of the PRNP are the only known causes of IPD [2]. These fatal neurodegenerative disorders follow a dominant mode of inheritance and are traditionally classified clinically as CJD, GSS, and FFI [22]. PRNP mutations consist of point mutations leading to an amino acid substitution or a premature stop codon, and insertions/deletions of additional (more than three additional) octapeptide repeats (OPRI/OPRD) in the region between codons 51–91 of the PrP that encodes a 5-mer repeat region consisting of a nonapeptide followed by four identical octapeptides. The frequency and distribution of these mutations differ between Europeans and East Asians [23]. Some pathogenic PRNP mutations are typically associated with particular clinical categories of prion disease [23], conferring the diagnosis of IPD and sub-classification according to a specific mutation (Table 1). Other mutations are involved in a spectrum of clinical and pathological phenotypes that vary across and within families carrying the same genetic alteration [24], often with striking phenotypic heterogeneity. In addition, different PRNP gene mutations have been suggested to play a potential role in clinical pictures mimicking other neurodegenerative diseases, such as Frontotemporal dementia (FTD) [25][26][27][28][29][30], Cerebral amyloid angiopathy (CAA) [5], familial neuropsychiatric illness [31], familial Alzheimer’s disease (AD) [32], and Huntington’s disease [33]; whereas the clinical picture may not be specific or confined to psychiatric features [24]. Of note, the most prevalent missense mutations causing IPD and a series of Single Nucleotide Polymorphisms (SNPs) are localized in the C-terminal domain. Conversely, in the N-terminal region between codons 51–91 (the region consisting of the octapeptide repeats), only OPRI/OPRD are found as polymorphisms and pathogenic mutations. The presence of any pathogenic point mutation in residues 23–50 remained unknown until the description of the missense Pro39Leu mutation, reported in two patients affected by FTLD syndrome [34] and successively in another FTD patient [35], in which all three patients were negative for mutations in other known causative genes. Pro39Leu is the first mutation described in the N-terminal domain located in a codon (the 39 codons), before the known 102 residue (pathogenic mutation Pro102Leu causative of GSS) [36]. Nevertheless, functional studies to determine whether and how the Pro39Leu mutation may exert its pathogenic effects still remain to be implemented. Recently, a PRNP mutation was described in a young GSS patient, presenting a particular clinical picture with status epilepticus at the age of 34, prefaced by night terrors at age 26, memory problems, behavioral changes and parasomnias subsided after a six-year period, emerged at this age [37]. This mutation consists of a LGGLGGYV insertion (a partial internal duplication) located at the junction between the hydrophobic region of the N-terminus and the globular domain. A subsequent study [38], involving animal modeling, defined a novel misfolded form of mutant PrPC that prefigures the PrP mutated fragment pathognomonic for end-stage GSS with multicentric amyloid plaques [39] that might also be shared by other forms of GSS, thus providing a potential explanation for the early disease onset of the proband.
Table 1. PRNP mutations and associated phenotypes [34][35][21][23].
Mutation Domain Clinical Phenotype
Pro39Leu N-terminal FTLD, FTD
Pro102Leu N-terminal Classical CJD-like symptoms, GSS
Pro105Leu N-terminal GSS, spastic paraparesis and progressive dementia
Pro105Ser, Pro105Thr N-terminal GSS
Gly114Val N-terminal CJD, neuropsychiatric symptoms
Ala117Val N-terminal CJD, Progressive cortical dementia and cerebellar ataxia
Octapeptide insertions (from 4 to 9 OR insertions) N-terminal CJD
Gly131Val C-terminal GSS, tremor and apraxia
Gln160-nonsense; Tyr163-nonsense C-terminal Alzheimer’s disease-type pathology
Val176Gly C-terminal Cerebellum ataxia, personality changes and progressive dementia
Asp178Asn C-terminal CJD and FFI depends on the allele on codon 129, Met or Val
Val189Ile C-terminal Classical and atypical CJD (behavioral abnormalities, ataxia and extrapyramidal features)
Val180Ile, Thr183Ala, Thr188Lys, Glu196Lys, Glu196Ala, Glu200Lys, Glu200Gly, Val203Ile, Arg208His, Val210Ile, Glu211Gln, Ile215Val C-terminal Classical and atypical CJD
Gln160-nonsense, His187Arg, Phe198Ser, Asp202Asn, Glu2011Gln, Gln212Pro, Gln217Arg, Tyr226-nonsense, Gln227-nonsense C-terminal Classical and atypical GSS
In addition to these mutations, that appear fully penetrant, many common single nucleotide polymorphisms (SNPs) have also been detected in the ORF of the PRNP gene [40]. The most important are the SNPs at codon 129, which have a critical role in susceptibility and as a modifier of prion disease, and alterations in the number of repeats, with up to three additional repeats. This specific genotype of the PRNP Met129Val SNP is responsible for the diagnosis of FFI or GSS (Table 1) when associated with the PRNP Asp178Asn mutation. Specifically, the Asp178Asn mutation accounts for FFI together with the 129Met genotype, whereas the same mutation associated with the 129Val genotype has been found in CJD (Table 1). Furthermore, the Met129Val SNP seems to be accountable for the phenotypic heterogeneity, such as variance in the age of onset (20–85 years) [24]. Other naturally occurring PRNP polymorphisms, such as the Gly127Val [41] and the Glu219Lys [42], completely prevent prion disease. In fact, it has been reported that the Gly127Val SNP in the heterozygous state was subjected to positive evolutionary selection during the epidemic of Kuru (an acquired prion disease epidemic of the Fore population in Papua, New Guinea), providing strong protection against the disease [41]. The Glu219Lys is also a PRNP SNP well-known for its protective effects against sporadic CJD [42], and the equivalent substitution in mouse PrP (Gln218Lys) is also protective against mouse-adapted scrapie [43]. It is possible that these effects depend on the inability of Glu219Lys to transform into PrPSc and on its dominant-negative inhibition of the coexisting wild-type PrP [44].

References

  1. Baiardi, S.; Rossi, M.; Capellari, S.; Parchi, P. Recent advances in the histo-molecular pathology of human prion disease. Brain Pathol. 2019, 29, 278–300.
  2. Prusiner, S.B.; Scott, M.R.; DeArmond, S.J.; Cohen, F.E. Prion protein biology. Cell 1998, 93, 337–348.
  3. Ironside, J.W.; Ritchie, D.L.; Head, M.W. Prion diseases. Handb. Clin. Neurol. 2017, 145, 393–403.
  4. Chen, C.; Dong, X.-P. Epidemiological characteristics of human prion diseases. Infect. Dis. Poverty 2016, 5, 47.
  5. Ghetti, B.; Piccardo, P.; Zanusso, G. Dominantly inherited prion protein cerebral amyloidoses—A modern view of Gerstmann-Sträussler-Scheinker. Handb. Clin. Neurol. 2018, 153, 243–269.
  6. Deleault, N.R.; Walsh, D.J.; Piro, J.R.; Wang, F.; Wang, X.; Ma, J.; Rees, J.R.; Supattapone, S. Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions. Proc. Natl. Acad. Sci. USA 2012, 10, E1938–E1946.
  7. Zafar, S.; Shafiq, M.; Andreoletti, O.; Zerr, I. Animal TSEs and public health: What remains of past lessons? PLoS Pathog. 2018, 14, e1006759.
  8. Weissmann, C.; Raeber, A.J.; Montrasio, F.; Hegyi, I.; Frigg, R.; Klein, M.A.; Aguzzi, A. Prions and the lymphoreticular system. Philos. Trans. R. Soc. B Biol. Sci. 2001, 356, 177–184.
  9. Taylor, D.R.; Hooper, N.M. The prion protein and lipid rafts. Mol. Membr. Biol. 2006, 23, 89–99.
  10. Wulf, M.-A.; Senatore, A.; Aguzzi, A. The biological function of the cellular prion protein: An update. BMC Biol. 2017, 15, 149.
  11. Puig, B.; Altmeppen, H.C.; Linsenmeier, L.; Chakroun, K.; Wegwitz, F.; Piontek, U.K.; Tatzelt, J.; Bate, C.; Magnus, T.; Glatzel, M. GPI-anchor signal sequence influences PrPC sorting, shedding and signalling, and impacts on different pathomechanistic aspects of prion disease in mice. PLoS Pathog. 2019, 15, e1007520.
  12. Zeng, L.; Zou, W.; Wang, G. Cellular prion protein (PrP(C)) and its role in stress responses. Int. J. Clin. Exp. Med. 2015, 15, 8042–8050.
  13. Brown, D.R.; Qin, K.; Herms, J.W.; Madlung, A.; Manson, J.; Strome, R.; Fraser, P.E.; Kruck, T.; Von Bohlen, A.; Schulz-Schaeffer, W.; et al. The cellular prion protein binds copper in vivo. Nature 1997, 390, 684–687.
  14. Burns, C.S.; Aronoff-Spencer, E.; Dunham, C.M.; Lario, P.; Avdievich, N.I.; Antholine, W.E.; Olmstead, M.M.; Vrielink, A.; Gerfen, G.J.; Peisach, J.; et al. Molecular features of the copper binding sites in the octarepeat domain of the prion protein. Biochemistry 2002, 41, 3991–4001.
  15. Burns, C.S.; Aronoff-Spencer, E.; Legname, G.; Prusiner, S.B.; Antholine, W.E.; Gerfen, G.J.; Peisach, J.; Millhauser, G.L. Copper coordination in the full-length, recombinant prion protein. Biochemistry 2003, 42, 6794–6803.
  16. Walter, E.D.; Stevens, D.J.; Spevacek, A.R.; Visconte, M.P.; Dei Rossi, A.; Millhauser, G.L. Copper binding extrinsic to the octarepeat region in the prion protein. Curr. Protein Pept. Sci. 2009, 10, 529–535.
  17. Brown, D.R.; Wong, B.-S.; Hafiz, F.; Clive, C.; Haswell, S.J.; Jones, I.M. Normal prion protein has an activity like that of superoxide dismutase. Biochem. J. 1999, 344, 1–5.
  18. Mouillet-Richard, S. Signal transduction through prion protein. Science 2000, 289, 1925–1928.
  19. Castle, A.R.; Gill, A.C. Physiological functions of the cellular prion protein. Front. Mol. Biosci. 2017, 4, 19.
  20. Machado, C.F.; Beraldo, F.H.; Santos, T.G.; Bourgeon, D.; Landemberger, M.C.; Roffé, M.; Martins, V.R. Disease-associated mutations in the prion protein impair laminin-induced process outgrowth and survival. J. Biol. Chem. 2012, 287, 43777–43788.
  21. OMIM Entry 176640—PRION PROTEIN; PRNP. Available online: https://www.omim.org/entry/176640 (accessed on 20 May 2019).
  22. Elahi, F.M.; Miller, B.L. A clinicopathological approach to the diagnosis of dementia. Nat. Rev. Neurol. 2017, 13, 457–476.
  23. Bagyinszky, E.; Van Giau, V.; Youn, Y.C.; An, S.S.A.; Kim, S. Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases. Neuropsychiatr. Dis. Treat. 2018, 14, 2067–2085.
  24. Minikel, E.V.; Vallabh, S.M.; Lek, M.; Estrada, K.; Samocha, K.; Sathirapongsasuti, J.F. Quantifying prion disease penetrance using large population control cohorts. Sci. Transl. Med. 2016, 8, 322ra9.
  25. Nitrini, R.; Da Silva, L.S.T.; Rosemberg, S.; Caramelli, P.; Carrilho, P.E.M.; Iughetti, P.; Passos-Bueno, M.R.; Zatz, M.; Albrecht, S.; Leblanc, A. Prion disease resembling frontotemporal dementia and parkinsonism linked to chromosome 17. Arq. Neuro-Psiquiatr. 2001, 59, 161–164.
  26. Hall, D.A.; Leehey, M.A.; Filley, C.M.; Steinbart, E.; Montine, T.; Schellenberg, G.D.; Bosque, P.; Nixon, R.; Bird, T. PRNP H187R mutation associated with neuropsychiatric disorders in childhood and dementia. Neurology 2005, 64, 1304–1306.
  27. Woulfe, J.; Kertesz, A.; Frohn, I.; Bauer, S.; George-Hyslop, P.S.; Bergeron, C. Gerstmann-Sträussler-Scheinker disease with the Q217R mutation mimicking frontotemporal dementia. Acta Neuropathol. 2005, 110, 317–319.
  28. Clerici, F.; Elia, A.; Girotti, F.; Contri, P.; Mariani, C.; Tagliavini, F.; Di Fede, G. Atypical presentation of Creutzfeldt–Jakob disease: The first Italian case associated with E196K mutation in the PRNP gene. J. Neurol. Sci. 2008, 275, 145–147.
  29. Giovagnoli, A.R.; Di Fede, G.; Aresi, A.; Reati, F.; Rossi, G.; Tagliavini, F. Atypical frontotemporal dementia as a new clinical phenotype of Gerstmann-Straussler-Scheinker disease with the PrP-P102L mutation. Description of a previously unreported Italian family. Neurol. Sci. 2008, 29, 405–410.
  30. Kumar, N.; Boeve, B.F.; Boot, B.P.; Orr, C.F.; Duffy, J.; Woodruff, B.K.; Nair, A.K.; Ellison, J.; Kuntz, K.; Kantarci, K.; et al. Clinical characterization of a kindred with a novel 12-octapeptide repeat insertion in the prion protein gene. Arch. Neurol. 2011, 68, 1165–1170.
  31. Samaia, H.B.; Mari, J.D.J.; Vallada, H.P.; Moura, R.P.; Simpson, A.J.G.; Brentania, R.R.; Mari, J.J.; Brentani, R.R. A prion-linked psychiatric disorder. Nature 1997, 390, 241.
  32. Finckh, U.; Müller-Thomsen, T.; Mann, U.; Eggers, C.; Marksteiner, J.; Meins, W.; Binetti, G.; Alberici, A.; Hock, C.; Nitsch, R.M.; et al. High Prevalence of Pathogenic Mutations in Patients with Early-Onset Dementia Detected by Sequence Analyses of Four Different Genes. Am. J. Hum. Genet. 2000, 66, 110–117.
  33. Collinge, J.; Brown, J.; Hardy, J.; Mullan, M.; Rossor, M.N.; Baker, H.; Crow, T.J.; Lofthouse, R.; Poulter, M.; Ridley, R.; et al. Inherited prion disease with 144 base pair gene insertion. Clinical and pathological features. Brain 1992, 115 Pt 3, 687–710.
  34. Bernardi, L.; Cupidi, C.; Frangipane, F.; Anfossi, M.; Gallo, M.; Conidi, M.E.; Vasso, F.; Colao, R.; Puccio, G.; Curcio, S.A.; et al. Novel N-terminal domain mutation in prion protein detected in 2 patients diagnosed with frontotemporal lobar degeneration syndrome. Neurobiol. Aging 2014, 35, 2657.e7–2657.e11.
  35. Oldoni, E.; Fumagalli, G.G.; Serpente, M.; Fenoglio, C.; Scarioni, M.; Arighi, A.; Bruno, G.; Talarico, G.; Confaloni, A.; Piscopo, P.; et al. PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population. J. Alzheimers Dis. 2016, 50, 353–357.
  36. Bernardi, L.; Cupidi, C.; Bruni, A.C. Pathogenic mechanisms of the prion protein gene mutations: A review and speculative hypotheses for pathogenic potential of the Pro39Leu mutation in the associated FTD-like phenotype. J. Neurol. Neurosci. 2017, 8, 208.
  37. Hinnell, C.; Coulthart, M.B.; Jansen, G.H.; Cashman, N.R.; Lauzon, J.; Clark, A.; Costello, F.; White, C.; Midha, R.; Wiebe, S.; et al. Gerstmann-Straussler-Scheinker disease due to a novel prion protein gene mutation. Neurology 2011, 76, 485–487.
  38. Mercer, R.C.C.; Daude, N.; Dorosh, L.; Fu, Z.-L.; Mays, C.E.; Gapeshina, H.; Wohlgemuth, S.L.; Acevedo-Morantes, C.Y.; Yang, J.; Cashman, N.R.; et al. A novel Gerstmann-Sträussler-Scheinker disease mutation defines a precursor for amyloidogenic 8 kDa PrP fragments and reveals N-terminal structural changes shared by other GSS alleles. PLoS Pathog. 2018, 14, e1006826.
  39. Parchi, P.; Chen, S.G.; Brown, P.; Zou, W.; Capellari, S.; Budka, H.; Hainfellner, J.; Reyes, P.F.; Golden, G.T.; Hauw, J.J.; et al. Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Straussler-Scheinker disease. Proc. Natl. Acad. Sci. USA 1998, 95, 8322–8327.
  40. Atkinson, C.J.; Zhang, K.; Munn, A.L.; Wiegmans, A.; Wei, M.Q. Prion protein scrapie and the normal cellular prion protein. Prion 2016, 10, 63–82.
  41. Asante, E.A.; Smidak, M.; Grimshaw, A.; Houghton, R.; Tomlinson, A.; Jeelani, A.; Jakubcova, T.; Hamdan, S.; Richard-Londt, A.; Linehan, J.M.; et al. A naturally occurring variant of the human prion protein completely prevents prion disease. Nature 2015, 522, 478–481.
  42. Shibuya, S.; Higuchi, J.; Tateishi, J.; Kitamoto, T.; Shin, R.-W.; Shin, R. Codon 219 lys allele of PRNP is not found in sporadic Creutzfeldt-Jakob disease. Ann. Neurol. 1998, 43, 826–828.
  43. Perrier, V.; Kaneko, K.; Safar, J.; Vergara, J.; Tremblay, P.; DeArmond, S.J.; Cohen, F.E.; Prusiner, S.B.; Wallace, A.C. Dominant-negative inhibition of prion replication in transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99, 13079–13084.
  44. Kaneko, K.; Zulianello, L.; Scott, M.; Cooper, C.M.; Wallace, A.C.; James, T.L.; Cohen, F.E.; Prusiner, S.B. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl. Acad. Sci. USA 1997, 94, 10069–10074.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Neurosciences
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Livia Bernardi
View Times: 714
Revisions: 3 times (View History)
Update Date: 13 Jan 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback